Welcome to our dedicated page for RenovoRx news (Ticker: $RNXT), a resource for investors and traders seeking the latest updates and insights on RenovoRx stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect RenovoRx's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of RenovoRx's position in the market.
Rhea-AI Summary
RenovoRx, Inc. (Nasdaq: RNXT) announced the expansion of their clinical development pipeline in preparation for the commencement of the CouGar Trial, a second Phase III trial evaluating RenovoGem in bile duct cancer. The trial aims to evaluate the safety and efficacy of intravenous chemotherapy versus Trans-Arterial Micro-Perfusion via RenovoGem with intravenous durvalumab for unresectable, locally advanced eCCA. The study brings hope for a new treatment option for patients diagnosed with this aggressive cancer, addressing the urgent clinical need for a safe and effective therapy in this important patient population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.72%
Tags
-
Rhea-AI Summary
RenovoRx, Inc. (Nasdaq: RNXT) announces positive research supporting RenovoGem™ and TAMP™ therapy platform for Locally Advanced Pancreatic Cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.16%
Tags
-
Rhea-AI Summary
RenovoRx, Inc. (Nasdaq: RNXT) has filed an international patent application for its Trans-Arterial Micro-Perfusion (TAMP) therapy platform, expanding its IP coverage for delivering therapeutic classes across DNA/RNA altering modalities, cell therapy, and antibody-based therapies. The company holds 9 issued patents and 9 pending patents for its TAMP platform and delivery system in the US, EU, and Asia. The new patent application aims to provide a novel and important pathway for targeted delivery of therapeutic classes, with the potential to open up new market potential and expand the upside value proposition of TAMP commercially. RenovoRx is currently investigating TAMP in its Phase III TIGeR-PaC clinical trial for the treatment of Locally Advanced Pancreatic Cancer (LAPC) following stereotactic body radiation therapy (SBRT).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.35%
Tags
Rhea-AI Summary
RenovoRx, Inc. (Nasdaq: RNXT) appoints Dr. Michel Ducreux, a renowned oncologist, to its Scientific Advisory Board. Dr. Ducreux brings extensive experience in gastrointestinal oncology and research, and is expected to contribute to the advancement of the Company's novel clinical programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.86%
Tags
-
Rhea-AI Summary
RNXT - RenovoRx Announces Financial Results and Collaboration with Imugene for TAMP Platform Expansion. The company remains focused on advancing its Phase III TIGeR-PaC clinical trial for the treatment of LAPC. Collaboration with Imugene further validates the TAMP platform and will expand use of RenovoRx’s delivery platform beyond chemotherapy to immunotherapy. Financial results for the third quarter ended September 30, 2023, show a cash position of $3.2 million, increased R&D expenses, flat G&A expenses, a net loss of $1.4 million, and 10,693,080 outstanding shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-28.38%
Tags
-
Rhea-AI Summary
RenovoRx CEO Shaun Bagai to present at ROTH MKM Healthcare Opportunities Conference on October 12, 2023. Bagai will discuss recent milestones including research collaboration with Imugene and highlights from Phase III TIGeR-PaC study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.92%
Tags
Rhea-AI Summary
RenovoRx announces positive Phase III TIGeR-PaC interim study results, collaboration with Imugene, and financial results for Q2 2023. The study shows an 8-month delay in cancer progression, 6-month overall survival benefit, and 65% reduction in adverse effects. The collaboration aims to explore oncolytic virus therapy using RenovoRx's TAMP platform. Q2 financial results show $6.0 million in cash and cash equivalents, $1.9 million in R&D expenses, and $1.4 million in G&A expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.6%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
Rhea-AI Summary
RenovoRx presents positive data on RenovoGem in the treatment of locally advanced pancreatic cancer. The interim analysis shows an eight-month median progression-free survival benefit for patients receiving RenovoGem compared to standard-of-care. The study also demonstrates a 65% reduction in adverse events and a clinically meaningful overall survival trend. RenovoGem has the potential to change the treatment paradigm for pancreatic cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.37%
Tags
RenovoRx, Inc.
Nasdaq:RNXT
RNXT Rankings
RNXT Stock Data
31.13M
15.38M
11.77%
1.96%
0.1%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
SAN JOSE
About RNXT
renovorx is a medical device company headquartered in silicon valley, california. we are developing innovative solutions for targeted delivery of fluids, including diagnostic and therapeutic agents, to selected sites in the peripheral vascular system. the ability to deliver these materials at high concentration to specific vasculature, safely and without perfusion overlap to other regions, is a central paradigm of our technology. we have received fda clearance for the renovocath™ rc120 and are now introducing our innovative technology to the clinical market. renovorx is a highly motivated team with broad experience and an exciting vision for the future of targeted delivery. we are backed by a broad medical advisory board and a strong board of directors. please contact us at info@renovorx.com to learn more.